Chinese biopharmaceutical company 3SBio Inc (01530.HK) revealed on Sunday the launch of a collaboration agreement with Samsung Bioepis Co Ltd for the clinical development and commercialisation of multiple biosimilar candidates.
This partnership will cover the clinical development and commercialisation of multiple biosimilar candidates developed by Samsung Bioepis, including SB8 Bevacizumab biosimilar candidate (SB8) in China (excluding Hong Kong, Macau and Taiwan).
The indications of Bevacizumab biosimilar candidate in China will focus on metastatic colon cancer (mCRC) and Non-Small Cell Lung Cancer (NSCLC). Bevacizumab is a recombinant humanized monoclonal antibody and in 2004 it became the first clinically used angiogenesis inhibitor.
Under the terms of the agreement, Samsung Bioepis will be responsible for manufacturing and supply of the products and collaborate with 3SBio across clinical development, regulatory registration and commercialization in China.
In conjunction with the partnership, Samsung Bioepis will receive an upfront payment and product supply income from 3SBio and will be eligible for additional payments associated with pre-specified clinical and regulatory milestones. Further financial terms were not disclosed.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review